Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 3/20 | 0.97 |
| ▸ | LMNA | P02545 | 10/20 | 0.95 |
| ▸ | HTT | P42858 | 5/20 | 0.95 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.95 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.95 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.82 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.82 |
| ▸ | TSHR | P16473 | 5/20 | 0.82 |
| ▸ | MEN1 | O00255 | 4/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.82 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.82 |
| ▸ | MITF | O75030 | 1/20 | 0.82 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.80 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.80 |
| ▸ | GAA | P10253 | 2/20 | 0.76 |
| ▸ | THRB | P10828 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | IDE | P14735 | 1/20 | 0.65 |
| ▸ | XBP1 | P17861 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2496455 | 0.99 | SLC5A2 (1.00) | SLC5A2LMNAHTTALOX15HSD17B10 | |
| Hydrochloric Acid SCHEMBL29445223 | 0.97 | LMNA (1.00) | SLC5A2LMNAHTTALOX15HSD17B10 | |
| SCHEMBL2474484 | 0.91 | LMNA (0.98) | SLC5A2LMNAHTTALOX15HSD17B10 | |
| SCHEMBL14847726 | 0.91 | SLC5A2 (0.86) | SLC5A2LMNAHTTALOX15HSD17B10 | |
| SCHEMBL2496035 | 0.91 | LMNA (0.89) | SLC5A2LMNAHTTALOX15HSD17B10 | |
| SCHEMBL2494794 | 0.91 | LMNA (0.98) | SLC5A2LMNAHTTALOX15HSD17B10 | |
| SCHEMBL13332637 | 0.91 | SLC5A2 (0.86) | SLC5A2LMNAHTTALOX15HSD17B10 | |
| SCHEMBL2497664 | 0.90 | LMNA (0.98) | SLC5A2LMNAHTTALOX15HSD17B10 | |
| SCHEMBL2496102 | 0.90 | LMNA (0.98) | SLC5A2LMNAHTTALOX15HSD17B10 | |
| SCHEMBL2495262 | 0.88 | LMNA (0.91) | SLC5A2LMNAHTTALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871794-B2 | Small-molecule agonists for type-2 orexin receptor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-10-28 | — | — | US | disclosed |
| US-8258163-B2 | Small-molecule agonists for type-2 orexin receptor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-09-04 | — | — | US | disclosed |
| US-20110178079-A1 | GUANIDINE COMPOUNDS AS ANESTHETICS AND FOR TREATMENT OF NERVOUS SYSTEM DISORDERS | TAKTIX CORPORATION | 2011-07-21 | — | — | US | disclosed |
| US-20110166181-A1 | GUANIDINE COMPOUNDS AS ANESTHETICS AND FOR TREATMENT OF NERVOUS SYSTEM DISORDERS | TAKTIX CORPORATION | 2011-07-07 | — | — | US | disclosed |
| US-7868028-B2 | Guanidine compounds as anesthetics and for treatment of nervous system disorders | Drasner, Fred (US) | 2011-01-11 | — | — | US | disclosed |
| US-20100150840-A1 | Small-molecule agonists for type-2 orexin receptor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-06-17 | — | — | US | disclosed |
| US-20050228022-A1 | blocking voltage-sensitive sodium channels of neurons in a mammal comprising administering 1-benzyl-2-imino-3-(2-hydroxy-3-phenoxypropyl)benzimidazole; analgesics; neuroprotectants; anticonvulsants | TAKTIX CORPORATION (US) | 2005-10-13 | — | — | US | disclosed |
| EP-1551397-A2 | GUANIDINE COMPOUNDS AS ANESTHETICS AND FOR TREATMENT OF NERVOUS SYSTEM DISORDERS | MediQuest Therapeutics, Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2003105779-A2 | GUANIDINE COMPOUNDS AS ANESTHETICS AND FOR TREATMENT OF NERVOUS SYSTEM DISORDERS | TAKTIX CORPORATION (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100150840-A1 | Small-molecule agonists for type-2 orexin receptor | HCRTR2, HCRTR1, OXTR | SLC5A2 1397/4885LMNA 2921/4885HTT 988/4885 |
| US-20110166181-A1 | GUANIDINE COMPOUNDS AS ANESTHETICS AND FOR TREATMENT OF NERVOUS SYSTEM DISORDERS | CACNA1E, GRIA4, GRIA3 | SLC5A2 1700/4885LMNA 1775/4885HTT 1558/4885 |
| US-20050228022-A1 | blocking voltage-sensitive sodium channels of neurons in a mammal comprising administering 1-benzyl-2-imino-3-(2-hydroxy-3-phenoxypropyl)benzimidazole; analgesics; neuroprotectants; anticonvulsants | CACNA1E, CACNA1B, SCN1A | SLC5A2 2022/4885LMNA 610/4885HTT 1547/4885 |
| US-20110178079-A1 | GUANIDINE COMPOUNDS AS ANESTHETICS AND FOR TREATMENT OF NERVOUS SYSTEM DISORDERS | CACNA1E, GRIA4, GRIA3 | SLC5A2 1811/4885LMNA 1893/4885HTT 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.